Literature DB >> 1846970

The transcriptional transactivator of human foamy virus maps to the bel 1 genomic region.

A Rethwilm1, O Erlwein, G Baunach, B Maurer, V ter Meulen.   

Abstract

The human foamy virus (HFV) genome possesses three open reading frames (bel 1, 2, and 3) located between env and the 3' long terminal repeat. By analogy to other human retroviruses this region was selected as the most likely candidate to encode the viral transactivator. Results presented here confirmed this and showed further that a deletion introduced only into the bel 1 open reading frame of a plasmid derived from an infectious molecular clone of HFV abolished transactivation. In contrast, deletions in bel 2 and bel 3 had only minor effects on the ability to transactivate. The role of the bel 1 genomic region as a transactivator was further investigated by eukaryotic expression of a genome fragment of HFV spanning the bel 1 open reading frame. A construct expressing bel 1 under control of a heterologous promoter was found to transactivate the HFV long terminal repeat in a dose-dependent fashion. Furthermore, it is shown that the U3 region of the HFV long terminal repeat is sufficient to respond to the HFV transactivator.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1846970      PMCID: PMC50930          DOI: 10.1073/pnas.88.3.941

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

1.  Expression of the pX gene of HTLV-I: general splicing mechanism in the HTLV family.

Authors:  M Seiki; A Hikikoshi; T Taniguchi; M Yoshida
Journal:  Science       Date:  1985-06-28       Impact factor: 47.728

2.  Location of the trans-activating region on the genome of human T-cell lymphotropic virus type III.

Authors:  J Sodroski; R Patarca; C Rosen; F Wong-Staal; W Haseltine
Journal:  Science       Date:  1985-07-05       Impact factor: 47.728

3.  Detailed analysis of the mouse H-2Kb promoter: enhancer-like sequences and their role in the regulation of class I gene expression.

Authors:  A Kimura; A Israël; O Le Bail; P Kourilsky
Journal:  Cell       Date:  1986-01-31       Impact factor: 41.582

4.  Identification of p40x-responsive regulatory sequences within the human T-cell leukemia virus type I long terminal repeat.

Authors:  J Brady; K T Jeang; J Duvall; G Khoury
Journal:  J Virol       Date:  1987-07       Impact factor: 5.103

5.  Human immunodeficiency virus 1 tat protein binds trans-activation-responsive region (TAR) RNA in vitro.

Authors:  C Dingwall; I Ernberg; M J Gait; S M Green; S Heaphy; J Karn; A D Lowe; M Singh; M A Skinner; R Valerio
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

6.  Human and simian immunodeficiency retroviruses: activation and differential transactivation of gene expression.

Authors:  S K Arya
Journal:  AIDS Res Hum Retroviruses       Date:  1988-06       Impact factor: 2.205

7.  Genomic organization of the human spumaretrovirus and its relatedness to AIDS and other retroviruses.

Authors:  B Maurer; R M Flügel
Journal:  AIDS Res Hum Retroviruses       Date:  1988-12       Impact factor: 2.205

8.  Analysis of the primary structure of the long terminal repeat and the gag and pol genes of the human spumaretrovirus.

Authors:  B Maurer; H Bannert; G Darai; R M Flügel
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

9.  Molecular cloning of the genome of human spumaretrovirus.

Authors:  A Rethwilm; G Darai; A Rösen; B Maurer; R M Flügel
Journal:  Gene       Date:  1987       Impact factor: 3.688

10.  Nucleotide sequence analysis of the env gene and its flanking regions of the human spumaretrovirus reveals two novel genes.

Authors:  R M Flügel; A Rethwilm; B Maurer; G Darai
Journal:  EMBO J       Date:  1987-07       Impact factor: 11.598

View more
  57 in total

1.  Complex effects of deletions in the 5' untranslated region of primate foamy virus on viral gene expression and RNA packaging.

Authors:  M Heinkelein; J Thurow; M Dressler; H Imrich; D Neumann-Haefelin; M O McClure; A Rethwilm
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

Review 2.  Mechanism of action of regulatory proteins encoded by complex retroviruses.

Authors:  B R Cullen
Journal:  Microbiol Rev       Date:  1992-09

3.  Cell cycle requirements for transduction by foamy virus vectors compared to those of oncovirus and lentivirus vectors.

Authors:  Grant Trobridge; David W Russell
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

Review 4.  Molecular biology of foamy viruses.

Authors:  Axel Rethwilm
Journal:  Med Microbiol Immunol       Date:  2010-05-06       Impact factor: 3.402

5.  Foamy virus vector integration sites in normal human cells.

Authors:  Grant D Trobridge; Daniel G Miller; Michael A Jacobs; James M Allen; Hans-Peter Kiem; Rajinder Kaul; David W Russell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-20       Impact factor: 11.205

6.  Distinct cis-acting regions in U3 regulate trans-activation of the human spumaretrovirus long terminal repeat by the viral bel1 gene product.

Authors:  L K Venkatesh; P A Theodorakis; G Chinnadurai
Journal:  Nucleic Acids Res       Date:  1991-07-11       Impact factor: 16.971

7.  Identification of a conserved residue of foamy virus Gag required for intracellular capsid assembly.

Authors:  S W Eastman; M L Linial
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

8.  Derivation and functional characterization of a consensus DNA binding sequence for the tas transcriptional activator of simian foamy virus type 1.

Authors:  Y Kang; B R Cullen
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  The human foamy virus Bel-1 transcription factor is a sequence-specific DNA binding protein.

Authors:  F He; W S Blair; J Fukushima; B R Cullen
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

Review 10.  Transgenic and knockout mice in the study of neurodegenerative diseases.

Authors:  A Aguzzi; S Brandner; S Marino; J P Steinbach
Journal:  J Mol Med (Berl)       Date:  1996-03       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.